论文部分内容阅读
数十年来深静脉血栓形成是用肝素治疗。肝素能防止已存在血栓的进展,并使其内源性纤维蛋白溶酶的活性破坏,多数复发性深静脉血栓形成病人都有内源性纤维蛋白溶酶活性的不足,应用链激酶治疗深静脉血栓形成可促使纤维蛋白溶酶防御系统迅速激活,致使血栓较快溶解。治疗时需要确定首次剂量并做一些化验,以免引起出血。三个对照研究证实,治疗深静脉血栓时链激酶比肝素更为有效。根据文献和作者个人积累的经验,在应用链激酶时可使链激酶的治疗标准化,而不须在治疗时确定其首次剂量和进行大量凝血因子及溶纤维蛋白成分的化验。
Deep venous thrombosis has been treated with heparin for decades. Heparin can prevent the progress of the existing thrombus, and the destruction of endogenous plasmin activity, the majority of patients with recurrent deep venous thrombosis have endogenous fibrinolytic activity deficiencies, the application of streptokinase for the treatment of deep veins Thrombosis can prompt rapid activation of the plasmin defensive system, resulting in rapid dissolution of thrombus. Treatment need to determine the first dose and do some tests, so as not to cause bleeding. Three controlled studies confirm that streptokinase is more effective than heparin in the treatment of DVT. Based on the literature and the authors’ personal experience, the treatment of streptokinase can be standardized when streptokinase is applied without the need to determine its first dose and to perform assays of a large number of coagulation factors and fibrinolytic components at the time of treatment.